-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Under the background of industry changes and intensified competition, the adjustment of the pharmaceutical industry will accelerate in 2022.
In order to cope with the market environment, the changes of executives of pharmaceutical companies have become more frequent
.
According to incomplete statistics, since the beginning of January 2022, more than 120 senior executives of pharmaceutical companies have changed, including the resignation of a large number of chairman of pharmaceutical companies.
The reasons for resignation are mainly personal reasons
.
Haili Bio On April 29, Haili Bio announced that the board of directors of the company recently received a resignation report from the company's chairman, Ms.
Zhang Yue.
Due to personal reasons, Ms.
Zhang Yue requested to resign as the company's chairman and director, chairman of the strategy committee and Member and Nomination Committee member positions
.
After resigning from the above positions, Ms.
Zhang Yue will not hold any position in the company
.
As of the date of this announcement, Ms.
Zhang Yue held 8,452,500 shares of the company, accounting for 1.
31% of the company's total share capital.
Ms.
Zhang Yue promised not to transfer the company's shares she held within 6 months after her resignation
.
Xinbang Pharmaceutical On April 13, Xinbang Pharmaceutical issued an announcement saying that due to personal reasons, Mr.
Anhualiu applied for his resignation as the chairman of the company
.
After Mr.
Ann Huailuo resigned, he will serve as a consultant to the company and no longer serve as a director, supervisor or senior executive of the company
.
At the end of March, Hainan Haiyao issued an announcement that the board of directors of the company received a written resignation application report from the chairman of the company, Mr.
Pan Dazhong, on March 26, 2022.
Mr.
Pan Dazhong was originally scheduled to serve until March 24, 2023.
Reasons to apply for resignation as the company's director, chairman, convener of the strategy committee of the board of directors and member of the nomination committee
.
After his resignation, Mr.
Pan Dazhong will not hold any position in the company
.
Heavy Pharmaceutical Holdings On March 11, Heavy Pharmaceutical Holdings announced that due to personal reasons, Liu Shaoyun applied to resign from the company's chairman, director, member and convener of the strategic development and investment committee of the board of directors, and member of the nomination committee of the board of directors
.
After Liu Shaoyun resigned from the above-mentioned positions, he took up a first-level professional position in the company.
The above-mentioned resignation report took effect from the date it was delivered to the board of directors
.
Harbin Pharmaceutical Group On February 12, Harbin Pharmaceutical Group announced that the company received a written resignation report submitted by director Zhang Zhenping
.
Due to retirement reasons, Zhang Zhenping resigned from the positions of vice chairman, director, and member of the Remuneration and Evaluation Committee, and will not hold any other positions in the company after resignation
.
Tianmushan Pharmaceutical On February 14, Tianmushan Pharmaceutical issued an announcement on the election of the chairman, vice chairman and adjustment of the special committee and the change of the legal representative
.
According to the announcement, according to relevant regulations, director Li Feng was elected as the chairman of the 11th board of directors of the company, and director Liu Bo was elected as the vice chairman of the 11th board of directors of the company.
until the expiry date
.
On January 10, Dong’e Ejiao announced that the board of directors of the company recently received a written resignation report submitted by chairman Han Yuewei.
Due to the change in work content, Han Yuewei applied to resign as chairman and director of the tenth board of directors of the company.
He also resigned as chairman of the strategy committee of the 10th board of directors of the company.
After resigning, Han Yuewei no longer held any positions in Dong'e Ejiao
.
It is worth mentioning that Dong’e Ejiao has changed coaches twice in three years, and at the end of 2019, Han Yuewei took over the position of chairman
.
Qin Yufeng, who had been chairman of the board for 14 years, resigned from the board of directors, president and legal representative one month after reaching the retirement age
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
In order to cope with the market environment, the changes of executives of pharmaceutical companies have become more frequent
.
According to incomplete statistics, since the beginning of January 2022, more than 120 senior executives of pharmaceutical companies have changed, including the resignation of a large number of chairman of pharmaceutical companies.
The reasons for resignation are mainly personal reasons
.
Haili Bio On April 29, Haili Bio announced that the board of directors of the company recently received a resignation report from the company's chairman, Ms.
Zhang Yue.
Due to personal reasons, Ms.
Zhang Yue requested to resign as the company's chairman and director, chairman of the strategy committee and Member and Nomination Committee member positions
.
After resigning from the above positions, Ms.
Zhang Yue will not hold any position in the company
.
As of the date of this announcement, Ms.
Zhang Yue held 8,452,500 shares of the company, accounting for 1.
31% of the company's total share capital.
Ms.
Zhang Yue promised not to transfer the company's shares she held within 6 months after her resignation
.
Xinbang Pharmaceutical On April 13, Xinbang Pharmaceutical issued an announcement saying that due to personal reasons, Mr.
Anhualiu applied for his resignation as the chairman of the company
.
After Mr.
Ann Huailuo resigned, he will serve as a consultant to the company and no longer serve as a director, supervisor or senior executive of the company
.
At the end of March, Hainan Haiyao issued an announcement that the board of directors of the company received a written resignation application report from the chairman of the company, Mr.
Pan Dazhong, on March 26, 2022.
Mr.
Pan Dazhong was originally scheduled to serve until March 24, 2023.
Reasons to apply for resignation as the company's director, chairman, convener of the strategy committee of the board of directors and member of the nomination committee
.
After his resignation, Mr.
Pan Dazhong will not hold any position in the company
.
Heavy Pharmaceutical Holdings On March 11, Heavy Pharmaceutical Holdings announced that due to personal reasons, Liu Shaoyun applied to resign from the company's chairman, director, member and convener of the strategic development and investment committee of the board of directors, and member of the nomination committee of the board of directors
.
After Liu Shaoyun resigned from the above-mentioned positions, he took up a first-level professional position in the company.
The above-mentioned resignation report took effect from the date it was delivered to the board of directors
.
Harbin Pharmaceutical Group On February 12, Harbin Pharmaceutical Group announced that the company received a written resignation report submitted by director Zhang Zhenping
.
Due to retirement reasons, Zhang Zhenping resigned from the positions of vice chairman, director, and member of the Remuneration and Evaluation Committee, and will not hold any other positions in the company after resignation
.
Tianmushan Pharmaceutical On February 14, Tianmushan Pharmaceutical issued an announcement on the election of the chairman, vice chairman and adjustment of the special committee and the change of the legal representative
.
According to the announcement, according to relevant regulations, director Li Feng was elected as the chairman of the 11th board of directors of the company, and director Liu Bo was elected as the vice chairman of the 11th board of directors of the company.
until the expiry date
.
On January 10, Dong’e Ejiao announced that the board of directors of the company recently received a written resignation report submitted by chairman Han Yuewei.
Due to the change in work content, Han Yuewei applied to resign as chairman and director of the tenth board of directors of the company.
He also resigned as chairman of the strategy committee of the 10th board of directors of the company.
After resigning, Han Yuewei no longer held any positions in Dong'e Ejiao
.
It is worth mentioning that Dong’e Ejiao has changed coaches twice in three years, and at the end of 2019, Han Yuewei took over the position of chairman
.
Qin Yufeng, who had been chairman of the board for 14 years, resigned from the board of directors, president and legal representative one month after reaching the retirement age
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
